USA flag logo/image

An Official Website of the United States Government

THE LONG-TERM OBJECTIVE OF THE PROPOSAL IS TO CREATE AND EVALUATE THE…

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
3018 		Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3018 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
Biological Therapeutics, Inc.
3505 Riverview Circle Moorhead, MN 56560
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: THE LONG-TERM OBJECTIVE OF THE PROPOSAL IS TO CREATE AND EVALUATE THE EFFECTIVENESS OF MONOCLONAL ANTIBODY DIRECTED AGAINST THE RECEPTOR ON MALIGNANT CELLS RECOGNIZED BY ACTIVATED MACROPHAGES.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE LONG-TERM OBJECTIVE OF THE PROPOSAL IS TO CREATE AND EVALUATE THE EFFECTIVENESS OF MONOCLONAL ANTIBODY DIRECTED AGAINST THE RECEPTOR ON MALIGNANT CELLS RECOGNIZED BY ACTIVATED MACROPHAGES. MACROPHAGES, WHEN ACTIVATED, RECOGNIZE AND DESTROY MALIGNANT CELLS. ACTIVATED MACROPHAGES DO NOT RECOGNIZE NONMALIGNANT CELLS. THE NATURE OF THIS RECEPTOR SITE IS UNKNOWN. IN THE CURRENT PHASE I PROPOSAL, USING NOVEL IMMUNIZATION PROTOCOLS, MONOCLONAL ANTIBODY WILL BE PRODUCED TO THAT RECOGNITION SITE. THE ANTIBODY WILL BE SCREENED IN APPROPRIATE ASSAYS FOR REACTIVITY WITH MALIGNANT AND NORMAL CELLS, INHIBITION OF BINDING, AND IMMUNOMODULATION. SUBSEQUENT PHASE II DEVELOPMENT WILL EVALUATE ITS ABILITY TO DESTROY TUMOR CELLS IN MODEL SYSTEMS BY VARIOUS MECHANISMS INCLUDING DIRECT TOXICITY, ANTIBODY-DEPENDENT CYTOTOXICITY AND THOROUGH IMMUNOTOXICITY CONJUGATES. ADDITIONAL DEVELOPMENT WOULD BE TO PROCEED TO PHASE I CLINICAL TRIALS. ALTERNATIVELY, THE ANTIBODY MAY BE USED TO PURIFY THE RECOGNITION SITE AND DEVELOP, USING THAT ANTIGEN, HUMAN MONOCLONAL ANTIBODIES.

Principal Investigator:

James r. hoffman
PRINCIPAL INVESTIGATOR
2182367648

Business Contact:

Small Business Information at Submission:

Biological Therapeutics, Inc.
3505 Riverview Circle Moorhead, MN 56560

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No